Publications by authors named "Michael Ruff"

Claim this Profile
R
RAP-103, a multi-chemokine receptor antagonist, displays anxiolytic-like effects and normalizes methamphetamine abstinence-induced behaviors in planarians.
Memunat Diekololaoluwa Abiru, Sonita Wiah, Meghana Dachepalli, Amy D Stringer, Michael R Ruff

Physiol Behav· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based on F-DOPA PET Images.
Jing Qian, Deanna Hasenauer, William G Breen, Paul D Brown, Christopher H Hunt, Michael W Ruff

Cancers (Basel)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker.
Jacob Guzzino, David J Crompton, Shubhi Agarwal, Shelby Kern, Aaron Bogan, Michael W Ruff

J Neurooncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of imaging signatures in F-DOPA PET of glioblastoma treated with dose-escalated radiotherapy.
Jing Qian, Deanna H Pafundi, William G Breen, Paul D Brown, Christopher H Hunt, Michael W Ruff

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Learning MRI Models for the Differential Diagnosis of Tumefactive Demyelination versus Wild-Type Glioblastoma.
Gian Marco Conte, Mana Moassefi, Paul A Decker, Matthew L Kosel, Christina B McCarthy, Michael W Ruff

AJNR Am J Neuroradiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.
Cecile Riviere-Cazaux, Michael B Keough, Jeffrey A Zuccato, Rahul Kumar, Sebastian Schulz, Michael W Ruff

Neuro Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis.
Bryan J Neth, Robert M Kraft, Kathryn L Eschbacher, Derek R Johnson, Paul A Decker, Michael W Ruff

J Neurooncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphoma.
Kun Yun, R Leo Sakemura, Ismail Can, Omar Gutierrez Ruiz, Ekene J Ogbodo, Michael W Ruff

Mol Ther Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma: utility for detection versus monitoring.
Cecile Riviere-Cazaux, Yuta Suzuki, Zain Kizilbash, William J Laxen, Jean M Lacey, Michael W Ruff

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA.
Cecile Riviere-Cazaux, Xiaoxi Dong, Wei Mo, Rahul Kumar, Chao Dai, Michael W Ruff

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas.
Sanghee Lim, Nathan H Clarke, Sara L Maloney, Ugur T Sener, Samantha J Caron, Michael W Ruff

J Neurooncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent adamantinomatous craniopharyngioma stabilized with tocilizumab and bevacizumab: illustrative case.
Lauren M Webb, Scott H Okuno, Ryan C Ransom, Jamie J Van Gompel, Allison L Humes, Michael W Ruff

J Neurosurg Case Lessons· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-course hypofractionated proton beam therapy, incorporating F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
Sujay Vora, Deanna Pafundi, Molly Voss, Matthew Buras, Jonathan Ashman, Michael Ruff

Lancet Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.
Arushi Khurana, Allison C Rosenthal, Razan Mohty, Mamatha Gaddam, Radhika Bansal, Michael W Ruff

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case of Long-Term Survival After Glioblastoma, IDH-Wild Type.
Lauren M Webb, Bryan J Neth, Aditya Raghunathan, Patricia T Greipp, Cristiane M Ida, Michael W Ruff

Neurologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case series of osseous metastases in patients with glioblastoma.
Lauren Michelle Webb, Mason J Webb, Jian L Campian, Samantha J Caron, Michael W Ruff

Medicine (Baltimore)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAT1-Associated Leukodystrophy Exacerbated by Classic Hodgkin Lymphoma-Directed Therapy.
Sara J Hooshmand, Karan L Chohan, Aditya Raghunathan, Deborah L Renaud, Michael W Ruff

Neurologist· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrP-CCR5 dependent pathway.
Marina I Oliveira da Silva, Miguel Santejo, Isaac W Babcock, Ana Magalhães, Laurie S Minamide, Michael Ruff

Cell Death Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
Karan L Chohan, Radhika Bansal, Matthew A Hathcock, Jonas Paludo, Nora N Bennani, Michael W Ruff

Leuk Lymphoma· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis.
William G Breen, Connie S Geno, Mark R Waddle, Jing Qian, William S Harmsen, Michael W Ruff

Neurooncol Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
R Leo Sakemura, Claudia Manriquez Roman, Paulina Horvei, Elizabeth L Siegler, James H Girsch, Michael W Ruff

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine Receptor Antagonists Prevent and Reverse Cofilin-Actin Rod Pathology and Protect Synapses in Cultured Rodent and Human iPSC-Derived Neurons.
Thomas B Kuhn, Laurie S Minamide, Lubna H Tahtamouni, Sydney A Alderfer, Keifer P Walsh, Michael R Ruff

Biomedicines· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery.
Bryan J Neth, Jeffrey L Winters, Revathi Thirumushi Sairaj, Ali Gharibi Loron, Masum Rahman, Michael W Ruff

Neurooncol Pract· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a Human Neuronal Culture System for the Study of Cofilin-Actin Rod Pathology.
Lubna H Tahtamouni, Sydney A Alderfer, Thomas B Kuhn, Laurie S Minamide, Soham Chanda, Michael R Ruff

Biomedicines· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
M J Webb, Bryan J Neth, Lauren M Webb, Jamie J Van Gompel, Michael J Link, Michael W Ruff

Neurooncol Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis